1-Naphthaleneacetic acid Clinical Trials

Size	Price	Qty
25mg	USD 97

Clinical Trials

Multiple clinical trials are evaluating therapeutic interventions across diverse conditions, including local anesthesia, mild cognitive impairment, Alzheimer's disease, metachromatic leukodystrophy, and Canavan disease. Spanning early Phase 1, Phase 1/2, and Phase 3 evaluations, alongside non-applicable phase designations, these studies maintain recruiting, active but not recruiting, and not yet recruiting statuses. They are spearheaded by academic and industry sponsors, including Radboud University Medical Center, Oregon Health and Science University with the Alzheimer's Association, Orchard Therapeutics, Ospedale San Raffaele, and Aspa Therapeutics.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06205680	Not yet recruiting	Anesthesia Local	Radboud University Medical Center	2024-03-01	Not Applicable
NCT05591027	Recruiting	Mild Cognitive Impairment\|Alzheimer''s Disease	Oregon Health and Science University\|Alzheimer''s Association	2022-12-01	Phase 1
NCT04283227	Active not recruiting	Lysosomal Storage Diseases\|Metachromatic Leukodystrophy	Orchard Therapeutics\|Ospedale San Raffaele	2022-01-17	Phase 3
NCT04998396	Recruiting	Canavan Disease	Aspa Therapeutics	2021-09-08	Phase 1\|Phase 2

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the 1-Naphthaleneacetic acid product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

1-Naphthaleneacetic acid binds to auxin co-receptor complexes, promoting the ubiquitin-mediated degradation of Aux/IAA repressor proteins and disinhibiting downstream transcriptional activation. This molecular cascade stimulates cell elongation, vascular differentiation, and tissue development, facilitating plant growth modulation while serving as a functional model in pharmacological research across neurological and metabolic condition contexts.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).